Skip to main
DNTH

DNTH Stock Forecast & Price Target

DNTH Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Dianthus Therapeutics Inc. presents a compelling investment opportunity due to its focused pipeline featuring DNTH103, a promising subcutaneous active C1s antibody aimed at treating severe autoimmune and inflammatory diseases. The company has demonstrated progress in its clinical trials, which enhances its differentiation from competitors and supports a positive outlook for future growth. Additionally, a strong cash runway extending into fiscal year 2028, coupled with a recent licensing agreement for DNTH212, positions Dianthus favorably for sustained development and commercialization efforts.

Bears say

Dianthus Therapeutics Inc. faces a challenging financial outlook due to concerns regarding its ability to secure adequate funding, which is essential for advancing its clinical pipeline. The removal of an assumed offering for FY28 and the lowered share count projections for FY25 indicate potential difficulties in financial planning and resource allocation. Without sufficient capital, the company's progress in developing its next-generation complement therapeutics may be significantly hindered, raising concerns about its long-term viability.

DNTH has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Magenta Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Magenta Therapeutics Inc (DNTH) Forecast

Analysts have given DNTH a Strong Buy based on their latest research and market trends.

According to 9 analysts, DNTH has a Strong Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $71.22, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $71.22, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Magenta Therapeutics Inc (DNTH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.